Nanobiotix

Nanobiotix is a late-stage clinical biotechnology company that is pioneering the discovery, development, manufacture, and commercialization of physics-based nanotherapeutics. Dedicated and driven, we take pride in delivering cutting-edge, effective treatments to patients and value to our stakeholders. We aim to create products that will transform outcomes for millions of people fighting cancer worldwide. Our lead candidate NBTXR3 is a potential first-in-class radioenhancer with therapeutic applications across a range of solid tumors. We believe that NBTXR3 offers broad potential to help patients fight cancer. Our initial focus on head and neck cancer aims to help a vulnerable patient population with limited treatment options and provide the clinical foundation for expansion across indications and therapeutic combinations. We pride ourselves in collaborating with institutions that share our vision of developing safer, more effective therapies for people with cancer and other challenging diseases. Delve deeper into our research, presentations, and videos about our mission and our transformative science.